Crossmark

The Novel C5aR Antagonist DF3016A Protects Neurons Against Ischemic Neuroinflammatory Injury

Crossref DOI link: https://doi.org/10.1007/s12640-019-00026-w

Published Online: 2019-04-05

Published Print: 2019-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Brandolini, Laura

Grannonico, Marta

Bianchini, Gianluca

Colanardi, Alessia

Sebastiani, Pierluigi

Paladini, Antonella

Piroli, Alba

Allegretti, Marcello

Varrassi, Giustino

Di Loreto, Silvia http://orcid.org/0000-0002-8256-5819
Funding

Funding for this research was provided by:

Fondazione P. Procacci (Prot.n. 1938)

Dompè Farmaceutici SpA (MTA 06/2016)
License Information

Text and Data Mining valid from 2019-04-05
More Information

Article History

Received: 4 December 2018

Revised: 14 March 2019

Accepted: 15 March 2019

First Online: 5 April 2019

Change Date: 6 May 2019

Change Type: Correction

Change Details: The article The Novel C5aR Antagonist DF3016A Protects Neurons Against Ischemic Neuroinflammatory Injury, written by Laura Brandolini, Marta Grannonico, Gianluca Bianchini, Alessia Colanardi, Pierluigi Sebastiani, Antonella Paladini, Alba Piroli, Marcello Allegretti, and Giustino Varrassi.

Compliance with Ethical Standards

:

: Laura Brandolini, Gianluca Bianchini, and Marcello Allegretti are employees of Dompé Farmaceutici SpA, Italy. The company has interests in the development of C5aR antagonists for the treatment of pain conditions. The other authors declare that they have no conflict of interest.

: All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice where the studies were conducted.